The company is also exploring MariTides potential for treating additional conditions, such as non-alcoholic steatohepatitis (NASH), now known as metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes

Common Cagrilintide Reconstitution Setups Vial Size 5 mg BAC Water 2.0 mL Concentration 2.5 mg/mL 0.6 mg Draw 0.24 mL / 24 units 1.2 mg Draw 0.48 mL / 48 units 2.4 mg Draw 0.96 mL / 96 units 4.5 mg Draw 1.80 mL / 180 units* Vial Size 5 mg BAC Water 3.0 mL Concentration 1.67 mg/mL 0.6 mg Draw 0.36 mL / 36 units 1.2 mg Draw 0.72 mL / 72 units 2.4 mg Draw 1.44 mL / 144 units* 4.5 mg Draw Exceeds vial Vial Size 10 mg BAC Water 2.0 mL Concentration 5.0 mg/mL 0.6 mg Draw 0.12 mL / 12 units 1.2 mg Draw 0.24 mL / 24 units 2.4 mg Draw 0.48 mL / 48 units 4.5 mg Draw 0.90 mL / 90 units Vial Size 10 mg BAC Water 3.0 mL Concentration 3.33 mg/mL 0.6 mg Draw 0.18 mL / 18 units 1.2 mg Draw 0.36 mL / 36 units 2.4 mg Draw 0.72 mL / 72 units 4.5 mg Draw 1.35 mL / 135 units* *Draws above 1.0 mL exceed standard 1 mL U-100 syringe capacity and may require a larger syringe or split injections
J Clin Med
By combining product versatility with strategic distribution channels, supplement distributors can strengthen market presence, capture consumer demand, and establish a competitive edge in the fast-growing GLP1 and gut health supplement category
Nat Rev Drug Discov 3:711715 Lau J, Bloch P, Schaffer L, Pettersson I, Spetzler J, Kofoed J, Madsen K, Knudsen LB, Mcguire J, Steensgaard DB, Strauss HM, Gram DX, Knudsen SM, Nielsen FS, Thygesen P, Reedtz-Runge S, Kruse T (2015) Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) Analogue semaglutide